Takeda Pharmaceutical expects to absorb a $2.5 billion financial hit following its loss in an antitrust lawsuit over the laxative drug Amitiza, the company disclosed in an update to its financial results on June 8, 2026.

The litigation concerns claims that Takeda's conduct around Amitiza, a treatment for chronic constipation, violated antitrust law. In May, a jury sided against the Japanese pharmaceutical company. Takeda has now adjusted its reported financial results to reflect the costs it could incur from the adverse verdict.

The $2.5 billion figure represents Takeda's current estimate of the exposure created by the jury's decision. It is a substantial charge for the company, and Takeda moved quickly to quantify the potential liability for investors after the May ruling.

Takeda is not accepting the outcome as final. The company has confirmed plans to appeal the verdict, meaning the ultimate financial consequence of the case could change depending on the result of appellate review. Until that process concludes, the $2.5 billion charge reflects the company's assessment of its position under the judgment as it stands.

The case adds Takeda's name to the list of major pharmaceutical manufacturers that have faced antitrust litigation over their marketed drugs in United States courts. Amitiza, the medicine at the center of the dispute, has been the subject of claims that Takeda contested before the jury earlier this year.

For practitioners, the development carries two practical signals. First, Takeda's decision to restate its financial expectations so soon after the May verdict illustrates how quickly a jury loss in pharmaceutical antitrust litigation can translate into a quantified, disclosed liability on a company's books. Second, the company's stated intention to appeal keeps the matter in active litigation, and the eventual appellate rulings in the case may prove significant for how similar drug-market antitrust claims are assessed going forward.

Takeda has not indicated that it will abandon its defense of the Amitiza-related claims. Its appeal will seek to overturn or narrow the verdict that produced the $2.5 billion exposure.

The company's updated results, published June 8, 2026, bring the financial impact of the Amitiza antitrust verdict into the public record while the legal fight continues.